Ensign Peak Advisors’s Gossamer Bio GOSS Stock Holding History

Ensign Peak Advisors’s Portfolio GOSS Stock Details GOSS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$239K	Sell	18,137 -3,140	-15%	-$70.1K	﹤0.01%	1283
2026 Q1	$559K	Buy	+21,277	New	+$2.68M	﹤0.01%	935
2023 Q3	–	Sell	-15,475	Closed	-$1.49M	–	1760
2023 Q2	$1.49M	Buy	15,475 +13,662	+754%	+$1.36M	﹤0.01%	989
2023 Q1	$183K	Hold	1,813	–	–	﹤0.01%	1742
2022 Q4	$315K	Sell	1,813 -257	-12%	-$169K	﹤0.01%	1704
2022 Q3	$1.98M	Buy	2,070 +56	+3%	+$55.6K	﹤0.01%	785
2022 Q2	$1.35M	Buy	2,014 +124	+7%	+$76.9K	﹤0.01%	974
2022 Q1	$1.31M	Hold	1,890	–	–	﹤0.01%	1056
2021 Q4	$1.71M	Buy	1,890 +77	+4%	+$73.2K	﹤0.01%	1023
2021 Q3	$1.82M	Hold	1,813	–	–	﹤0.01%	1181
2021 Q2	$1.18M	Hold	1,813	–	–	﹤0.01%	1379
2021 Q1	$1.34M	Sell	1,813 -469	-21%	-$378K	﹤0.01%	1301
2020 Q4	$1.77M	Hold	2,282	–	–	﹤0.01%	1135
2020 Q3	$2.26M	Sell	2,282 -153	-6%	-$162K	0.01%	891
2020 Q2	$2.53M	Sell	2,435 -153	-6%	-$154K	0.01%	846
2020 Q1	$2.1M	Sell	2,588 -591	-19%	-$617K	0.01%	805
2019 Q4	$3.98M	Buy	+3,179	New	+$5.12M	0.01%	715

Other funds holding GOSS

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

DeepCurrents Investment Group New York $3.3B AUM 12.57% 1-Year Est. Return

Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Ensign Peak Advisors's GOSS Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Gossamer Bio (GOSS) stake by 15% in Q2 2026, selling an estimated $70.1K and leaving 18,137 shares worth $239K. The position accounts for ﹤0.01% of the portfolio, ranked #1283.

Ensign Peak Advisors first reported a position in GOSS in Q4 2019 and has held it in 17 quarters since. The position peaked at $3.98M in Q4 2019. 166 funds tracked by Wall St. Rank hold GOSS as of Q2 2026.

Ensign Peak Advisors held 18,137 shares of Gossamer Bio worth $239K as of Q2 2026.
Ensign Peak Advisors sold 3,140 Gossamer Bio shares in Q2 2026, an estimated $70.1K.
Gossamer Bio made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #1283 holding.
Ensign Peak Advisors first reported a position in Gossamer Bio in Q4 2019 and has held it in 17 quarters since.
Ensign Peak Advisors's Gossamer Bio position peaked at $3.98M in Q4 2019.
166 funds tracked by Wall St. Rank held Gossamer Bio as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.